[Potential role of patient-derived tumor xenografts (PDTXs) in the selection of optimal therapeutic strategy].
The rapid selection of the efficient anticancer therapy may decrease the unwanted burden to patients and has financial consequences. Tumor models including xenografts in mice were used previously mostly in the development of new anticancer drugs. Nowadays xenografts from direct patient-derived tumor tissues (PDTT) in immune deficient mice yield better models than experimental tumors originating from cell cultures. The new method enables researchers to observe heterogeneous tumor cells with their surrounding tissue elements and matrices representing the clinical situation in humans much better. The cells in PDTT tumors are alive and functionally active through several generations after serial transplantation. Therefore using these models we may investigate tumor response to different therapies, the selection of resistant cell populations and the formation of metastasis predicting the outcomes in the personalized therapy.